Table 2.

Trial outcomes of patients randomised to convalescent plasma (CCP) compared with standard of care (SOC)

Outcome	Overall	CCP	SOC	RR*	P value
Primary outcome
Time to two consecutively negative reverse transcriptase-PCR, median (IQR), days	n=136	n=69	n=67
	5.5 (4–8)	6 (4–11)	4 (4–6)		0.196
Secondary outcomes
Time to symptom resolution among symptomatic patients, median (IQR)	n=120	n=59	n=61
	2 (1–4)	2 (1–4)	2 (1–4)		0.772
Progression to severe/critical disease (oxygen saturation <93% or needing oxygen)	n=70	n=41	n=29
	16 (22.9)	9 (22.0)	7 (24.1)	0.91 (0.38 to 2.16)	0.830
Mortality	n=136	n=69	n=67
	18 (13.2)	10 (14.5)	8 (11.9)		0.661

*Unadjusted risk ratio.